article thumbnail

Covid-19 induced immune response may damage brain, NINDS study finds

Pharmaceutical Technology

Scientists at the National Institutes of Health (NIH) unit National Institute of Neurological Disorders and Stroke (NINDS) have found that Covid-19-induced immune response could damage the blood vessels of the brain and may lead to short and long-term neurological symptoms. .

article thumbnail

Feinstein Institutes researchers discover new protein for sepsis treatment

Pharmaceutical Technology

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections.

Protein 263
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Team studies immune response, proteins in blood of young adults who develop rare complication after COVID vaccination

Medical Xpress

In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine.

article thumbnail

Curevac gets grant for pharmaceutical composition for rsv vaccine with modified fusion protein

Pharmaceutical Technology

Learn about the innovative pharmaceutical composition and method for stimulating a robust immune response against RSV. Discover Curevac NV's groundbreaking patent for an mRNA-based RSV vaccine, targeting prophylaxis and treatment.

article thumbnail

The Lancet Respiratory Medicine: Clinical trial finds inhaled immune response protein increases odds of recovery for hospitalised COVID-19 patients

Scienmag

Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.

article thumbnail

Study: Infection with common cold coronaviruses can trigger broad cross-immunity against SARS-CoV-2 proteins

Medical Xpress

Researchers at the University Medical Center Hamburg-Eppendorf have demonstrated cross-reactive immune responses to another SARS-CoV-2 protein besides the spike protein.

Protein 98
article thumbnail

The host immune response in COVID-19 and beyond

pharmaphorum

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. This is made possible using ‘Advanced Host Immune Response Technologies’. The pace of work in the industry reached almost ludicrous speeds.